Operational best practices
In response to the urgent need for a vaccine and treatment for COVID-19, researchers are, at this writing, running nearly 500 clinical trials (and counting) on a number of antivirals and vaccines.1
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus.
A compressed timeline with no room for error
Although COVID-19 has yet proven to be a seasonal disease, it will likely recycle with other respiratory pathogens in the winter respiratory season. With that said, Phase I and II studies can be executed any time, although off-season is typically preferred so as to not confound the data with natural disease acquisition. Phase III randomised, controlled efficacy studies of vaccines aimed at preventing laboratory-confirmed disease are typically executed with the season in mind and make for an intense time for sponsors, contract research organisations (CROs) and sites. They must contend with an aggressive calendar that compresses study start and recruitment, the need for active surveillance of thousands of patients, complex supply and site logistics, high volumes of data, and alternatives to on-site monitoring.
Geography and subject population
COVID-19 vaccine studies can be conducted anywhere in the world and can be designed around low or high incidence areas. Because regulatory agencies are prioritising COVID studies and giving approvals in record time, the geographies available for study are much more extensive than in the typical influenza or RSV study. Some countries or areas are yet to see spread of disease, and consideration should be given to including sites with or without current disease spread. Furthermore, thought should be given to whether subjects should be seronegative, which would also drive this decision. There are arguments that could be made for including both seronegative and seropositive subjects.
Planning
With respect to respiratory pandemic vaccine studies, the timeline is extraordinarily compressed, with potentially serious consequences for any delay or lack of attention to detail. The study must be the first priority for the team, and researchers and sponsors must consider new approaches for routine activities. The critical steps in the start-up process are to:
- Stabilise the protocol as quickly as possible. It is difficult to prepare an extensive study plan if the protocol is still in flux.
- Select the hemisphere and countries where the trial will run. These decisions will be based in part on answers to such questions as: Should subjects be seronegative or not? What type of volunteers should be considered, general population, older vs younger, healthcare workers etc.
- Develop the monitoring plan, along with any monitoring oversight plan. For pandemic vaccines, standard on-site visits may not be possible. Risk-based monitoring and options for remote visits and the use of video and data analytics should be considered.
- Develop the investigator budget. Given the number of subjects typically involved, the budget will be substantial and may include additional needs or challenges for the investigative site.
- Address contingencies in the manufacturing plan. With new vaccines in a pandemic situation, manufacturing will be tricky as the first lots don’t always pass the quality control/quality assurance process, delaying study start. Communicating the status transparently is critical so that all parties can make adjustments and be prepared for study start as soon as the vaccine can be shipped.
- Ensure the availability of equipment. To handle vaccines and lab specimens, sites must have centrifuges and refrigerators/freezers, and of course, personal protection equipment.
- Develop and stress test all systems. In the case of a pandemic vaccine, timelines for setting up and testing study systems such as eDiaries, EDC, interactive response technology (IRT), and electronic trial master files (eTMF) will be compressed significantly, and thus careful and thorough User Acceptance Tests (UATs) will be of utmost importance.
- Develop the data management plan and statistical analysis plan (SAP). Plans for data management and data cleaning as well as plans for interim and final data analysis should be set prior to the FSI.
Enrollment
All sites within a hemisphere should begin competitive enrollment on or around the same day. With a pandemic study, overall competitive enrollment with no caps should be considered as depending on disease spread, site capabilities, and changing needs, some sites may suddenly be unable to participate.
Adverse event reporting
General, adverse events (AEs) or medically-intended AEs are usually captured for 28 days post vaccination, while serious adverse events (SAEs) and new onset chronic conditions (NOCDs) are reported for the duration of the trial. For a COVID study, an eDiary may not be suited to collecting reactogenicity (solicited events) due to the setup time requires, thus paper diaries may be required.
Monitoring and study documentation
COVID-19 studies amidst an outbreak require new approaches to monitoring beyond the standard remote and on-site visits. This might include data analytics, remote monitoring using technology to conduct visits to verify facilities, inspect vaccine storage/handling as well as source data verification.
Data management
Data will be coming in very, very rapidly, and it is essential to clean it continuously, rather than letting it wait until just before the study closes. The same is true for serology data, viral swabs results, and the reconciliation of SAEs.
COVID-19 clinical operations
Keeping your clinical trial on track in an evolving environment.
Successful factors for COVID-19 studies
Respiratory vaccine studies are fast-paced from beginning to end, and pandemic studies move at lightning speed. In our experience, the keys to success include:
- Flexibility and thinking out of the box.
- Performing more activities in parallel in a shorter timeframe.
- Careful planning, effective communication, and close collaboration between the sponsor, the CRO, the sites, and other vendors.
- The ability to make decisions and resolve issues rapidly. Response time to questions and needs must be as short as possible. Within the same day is ideal.
- Making the study the top priority within the organisation with internal advocates and leadership support.
- Selecting investigative sites that are experienced in vaccine studies and have proven capabilities.
- Taking extraordinary steps to ensure the availability of the study vaccine and any comparator.
- Aggressively addressing any unanticipated delays.
- Using a robust system for tracking progress and gathering data.
- Designing monitoring plans to adapt to the various and changing sites’ needs.
- Considering out-of-the-box solutions to ensure rapid execution while maintaining high quality performance and documentation.
The scope and timeframes of pandemic studies such as COVID19-studies leave no room for error and have a very steep learning curve with limited leeway to learn on the job. As the world awaits a vaccine for COVID-19, Sponsors must respond with a comprehensive, coordinated approach that accounts for contingencies, properly manages risk, holds to a firm schedule and applies best practices developed through years of experience.
Reference
1 ClinicalTrials.gov.
MIT Technology Review article
Cindy Dukes provided commentary in a 26 May MIT Technology Review article:
Here’s what we have to do to show a coronavirus vaccine works
Infectious diseases and vaccines insights
ICON's Infectious Diseases and Vaccines teams contribute regularly to media and industry conversations in addition to the production of thought leadership content in the form of whitepapers and blogs.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel